Discover Algeria | Press area | Contact  
English Français
Registration
English Français
business-banner

September 3, 2025 | 1 month ago

  • More options

    Share on LinkedIn
    Share on Twitter

Saidal and AbbVie sign strategic agreement to strengthen pharmaceutical research in Algeria

On Tuesday, September 2, the state-owned pharmaceutical group Saidal signed a memorandum of understanding (MOU) with the American biopharmaceutical company AbbVie, represented in Algeria by Promedex. The announcement was made in an official press release from the Saidal group.

Algeria Invest
Legal Notices | Terms of Services
news-detail

The signing ceremony for a cooperation agreement took place at the headquarters of the Ministry of Pharmaceutical Industry, in the presence of senior officials from Saidal and the AbbVie group, as well as Minister Ouacim Kouidri. This partnership aims to strengthen the skills of the staff at the Equival Biocenter bioequivalence centre through certified training courses, specialized workshops, and the transfer of expertise in the fields of bioequivalence and clinical research.

Beyond training, the agreement paves the way for broader strategic collaboration, particularly in improving best practices in pharmaceutical manufacturing. Through this initiative, Saidal and AbbVie are expressing their shared commitment to promoting innovation and ensuring access to modern treatments for Algerian patients.

This project is part of Algeria's national strategy to strengthen its pharmaceutical sovereignty, develop clinical research, and position the country as a future regional hub for pharmaceutical biotechnology.

September 3, 2025 | algeria-logo

  • More options

    Share on LinkedIn
    Share on Twitter
Subscribe to the economic newsletter